Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02456883 | Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors | completed | Phase 1 | 6 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 5, 2024 | clinicaltrials |
| NCT04504669 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | completed | Phase 1 | 60 | AstraZenecaINDUSTRY | 4 | Nov 5, 2024 | clinicaltrials |
| NCT03666143 | A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 216 | BeiGeneINDUSTRY | 2 | Nov 4, 2024 | clinicaltrials |
| NCT01359982 | Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects(DINAMIC) | completed | Phase 1 | 26 | EpicentRx, Inc.INDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT03457532 | A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors | completed | Phase 1 | 177 | Haihe Biopharma Co., Ltd.INDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT03565445 | A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors | completed | Phase 1 | 190 | Astellas Pharma Global Development, Inc.INDUSTRY | 9 | Nov 1, 2024 | clinicaltrials |
| NCT02038673 | An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors | completed | Phase 1 | 86 | Astellas Pharma IncINDUSTRY | 4 | Oct 31, 2024 | clinicaltrials |
| NCT02383368 | A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma | completed | Phase 1 | 39 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT04096638 | Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors | completed | Phase 1 | 61 | invoX Pharma LimitedINDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT04742595 | Viral Specific T Cell Therapy for COVID-19 Related Pneumonia | completed | Early Phase 1 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT03994211 | Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer | completed | Phase 1 | 25 | BeiGeneINDUSTRY | 4 | Oct 26, 2024 | clinicaltrials |
| NCT04068519 | Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody | completed | Phase 1 / Phase 2 | 300 | BeiGeneINDUSTRY | 1 | Oct 26, 2024 | clinicaltrials |
| NCT03486730 | BT1718 in Patients with Advanced Solid Tumours. | completed | Phase 1 / Phase 2 | 72 | Cancer Research UKOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT03641586 | The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor | completed | Phase 1 | 42 | BeiGeneINDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT03323034 | Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 30 | Children's Oncology GroupNETWORK | 1 | Oct 22, 2024 | clinicaltrials |
| NCT05200013 | BAT7104 in Patients With Advanced Solid Tumours | completed | Phase 1 | 14 | Bio-Thera SolutionsINDUSTRY | 1 | Oct 18, 2024 | clinicaltrials |
| NCT05043298 | A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors | completed | Phase 1 | 12 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT02516813 | Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy | completed | Phase 1 | 52 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 8 | Oct 15, 2024 | clinicaltrials |
| NCT04908046 | A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors | completed | Phase 1 | 47 | HutchmedINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT03087591 | APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery | completed | Phase 1 | 11 | Wake Forest University Health SciencesOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05390710 | PhI to Solid Tumors and PhII to Locally Advanced or mTNBC | completed | Phase 1 | 21 | Laekna LimitedINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT03466268 | Study to Evaluate the Safety and Anti-tumor Activity of SCC244 | completed | Phase 1 | 56 | Haihe Biopharma Co., Ltd.INDUSTRY | 1 | Oct 9, 2024 | clinicaltrials |
| NCT05198089 | Development of a Digital Tool, MyInspiration, for the Improvement of Spiritual Well-Being in Patients with Cancer | completed | Phase 1 | 52 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT03936465 | Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer | completed | Phase 1 | 41 | Dana-Farber Cancer InstituteOTHER | 2 | Oct 2, 2024 | clinicaltrials |
| NCT03946800 | A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors | completed | Phase 1 | 61 | MedImmune LLCINDUSTRY | 2 | Oct 2, 2024 | clinicaltrials |
| NCT04659629 | NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer | completed | Phase 1 | 59 | Neurogene Inc.INDUSTRY | 3 | Oct 1, 2024 | clinicaltrials |
| NCT02791334 | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors(PACT) | completed | Phase 1 | 164 | Eli Lilly and CompanyINDUSTRY | 7 | Sep 27, 2024 | clinicaltrials |
| NCT02360345 | Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly(ONX-0801) | completed | Phase 1 | 111 | Royal Marsden NHS Foundation TrustOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT02389842 | PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib(PIPA) | completed | Phase 1 | 79 | Royal Marsden NHS Foundation TrustOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT03251378 | A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers | completed | Phase 1 | 129 | Hutchison Medipharma LimitedINDUSTRY | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06039137 | The Effect of Switching the H1-antagonist Clemastine to Cetirizine in Premedication Regimens During Paclitaxel Treatment(H1-Switch) | completed | — | 395 | Erasmus Medical CenterOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT04713891 | A Study of KF-0210 in Advanced Solid Tumors Patients | completed | Phase 1 | 14 | Keythera Pharmaceuticals (Australia) Pty LtdINDUSTRY | 1 | Sep 24, 2024 | clinicaltrials |
| NCT05717101 | Patient Registry in Patients Undergoing Contrast-Enhanced Harmonic Endoscopic Ultrasound Imaging | completed | — | 4 | Mayo ClinicOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT00483366 | Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 13 | University of NebraskaOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT03302325 | Circulating Tumor DNA As Liquid Biopsy in Patients with Stage IV Solid Tumors, a Feasibility Study At MUSC HCC | completed | — | 20 | Medical University of South CarolinaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03516123 | A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 18 | CStone PharmaceuticalsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03523819 | A Study of CS1002 in Subjects with Advanced Solid Tumors | completed | Phase 1 | 91 | CStone PharmaceuticalsINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT03744403 | A Study of CS1001 in Subjects with Advanced Solid Tumors | completed | Phase 1 | 24 | CStone PharmaceuticalsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03873883 | First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer(IO-001) | completed | Phase 1 | 119 | iTeos TherapeuticsINDUSTRY | 6 | Sep 19, 2024 | clinicaltrials |
| NCT04087018 | Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors | completed | Phase 1 | 18 | Arcus Biosciences, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04434482 | IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 59 | Impact Therapeutics, Inc.INDUSTRY | 5 | Sep 19, 2024 | clinicaltrials |
| NCT04474470 | A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer | completed | Phase 1 / Phase 2 | 52 | TyrNovo Ltd.INDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT04721223 | JAB-3068 Activity in Adult Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 12 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04742556 | A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive) | completed | Phase 1 | 15 | Boehringer IngelheimINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05002868 | Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors | completed | Phase 1 | 23 | Rhizen Pharmaceuticals SAINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT05058339 | Distress Associated with Coronavirus Disease 2019 and Telehealth on Supportive Care Patients with Advanced Cancer | completed | — | 223 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05117177 | New Formulation Study of Inupadenant (EOS100850) in Patients with Cancer | completed | Phase 1 | 57 | iTeos TherapeuticsINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT05224271 | Evaluating Patient Reported Outcomes in Radiation Therapy, the PRO-RT Study | completed | — | 18 | Mayo ClinicOTHER | 1 | Sep 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 5, 2024source: clinicaltrials